Targeting HER2

    • Monoclonal antibody targeting HER2, trastuzumab was first approved in 2006 for HER2+ breast cancer patients in combination therapy with chemotherapeutic agents. In 2010, trastuzumab was approved for metastatic gastric and gastroesophageal junction (GEJ) as combination front-line therapy with chemotherapy.
    • Pertuzumab, a monoclonal HER2 antibody, was approved as neoadjuvant therapy in combination with trastuzumab and docetaxel. A combination of trastuzumab and pertuzumab is currently in advanced-phase clinical trials in cancers with ERBB2 gene amplification and gene mutations.
    • Ado-trastuzumab (TDM-1) is an antibody–drug conjugate (ADC) that consists of trastuzumab linked with emtansine, a herapy was approved in 2013 for metastatic HER2+ breast cancer following progression on trastuzumab and taxane. TDM-1 in combination with lapatinib and abraxane for HER2+ metastatic breast cancers is in early-phase clinical trials.
    Other topics in Molecular Targets and Pathways